Viemed Healthcare earnings release, August 3, 2026

Viemed Healthcare, Inc. (VMD) · Form 8-K, Item 2.02 · Filed · SEC filing

VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three and six months ended June 30, 2026, and updated guidance for the full year ending December 31, 2026.

Operational highlights (all dollar amounts are USD):

• Net revenues for the quarter ended June 30, 2026 were $78.1 million, setting a Company record, representing an increase of $15.0 million, or 23.9%, compared with the prior-year quarter and an increase of approximately 3.6% sequentially.

• Net income attributable to Viemed for the quarter ended June 30, 2026 totaled $2.8 million, or $0.07 per diluted share.

• Adjusted EBITDA for the quarter ended June 30, 2026 totaled $13.7 million, a 4.0% decrease as compared to the quarter ended June 30, 2025. The prior year period included a $1.0 million non-recurring gain on disposal of property and equipment related to the ventilator return program, which benefited net income and concluded during 2025.

• Net cash provided by operating activities totaled $15.9 million for the quarter and $60.8 million for the trailing twelve months ended June 30, 2026. Free cash flow totaled $8.6 million for the quarter and $34.4 million for the trailing twelve months ended June 30, 2026.

• During the second quarter of 2026, the Company repurchased and cancelled 530,802 common shares under its share repurchase program at a cost of $5.1 million (excluding taxes), representing an average buyback price of $9.65 per share.

• The Company ended the second quarter of 2026 with a record 12,635 ventilator patients, an increase of 4.0% over June 30, 2025, and a 4.5% sequential increase from March 31, 2026.

• The Company increased its PAP therapy patient count to 37,825 as of June 30, 2026, an increase of 44.0% over June 30, 2025, and a 5.3% sequential increase from March 31, 2026. The Company's sleep resupply patient count was 37,035 as of June 30, 2026, up 46.7% year over year and 10.0% sequentially.

• As of June 30, 2026, the Company maintained a cash balance of $10.7 million and an overall working capital balance of $6.1 million. The Company repaid $2.2 million of its term loan during the quarter ended June 30, 2026. Long-term debt totaled $6.4 million and the Company has $46 million available under existing credit facilities.

Updated Full Year 2026 Guidance (all dollar amounts are USD):

Based on first-half performance and favorable operating trends across ventilation and the broader platform, the Company is raising the low end and narrowing the range of its full-year net revenue guidance. The Company is also revising its Adjusted EBITDA guidance and net capital expenditure outlook. The revised guidance reflects the growing contribution from less capital-intensive product and service revenue.

• Net revenue is now expected to be in the range of $314 million to $320 million, compared with the previous range of $312 million to $320 million.

• Adjusted EBITDA is now expected to range from $64 million to $68 million, compared with the previous range of $65 million to $69 million.

• Net capital expenditures are now expected to range from 8.5% to 10.0% of net revenue, compared with the previous range of 9.0% to 10.5%.

See “Use of Non-GAAP Financial Information and Financial Guidance” below for further information about non-GAAP financial measures and non-GAAP financial guidance.

Casey Hoyt, Viemed’s CEO, noted, “Viemed delivered another record quarter, with revenue reaching $78.1 million and our ventilator patient census rising to the highest level in company history. Strong ventilator setup activity, improving patient compliance, record PAP volume, and continued expansion in resupply and maternal health demonstrate the momentum building across our entire platform.”

“The strength of these results reflects the durable and increasingly diversified company we have built. Viemed has multiple growth engines, strong cash generation, a solid balance sheet, and the financial flexibility to continue investing in our people, technology, and patient care capabilities. We are making those investments deliberately to support the patient growth already entering the platform, and we enter the second half of 2026 confident in Viemed's ability to deliver consistent and increasingly predictable growth.”

Conference Call Details

The Company will host a conference call to discuss second quarter results on Tuesday, August 4, 2026, at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)

+1 201-689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=peVp8cbE

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of home medical equipment and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. Viemed’s model emphasizes efficient, high-quality care delivered in the home through a combination of high-touch clinical support and technology-enabled services, including therapy, education, and counseling provided by our clinical practitioners. For more information, visit our website at www.viemed.com.

For further information, please contact:

Investor Relations ir@viemed.com

Trae Fitzgerald

Chief Financial Officer

337-504-3802

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue78,09763,056153,511122,185
Cost of revenue33,04926,32565,63652,175
Gross profit45,04836,73187,87570,010
Operating expensesSelling, general and administrative37,13228,80371,92457,228
Operating expensesResearch and development5048471,0831,644
Operating expensesStock-based compensation2,0322,3414,4834,652
Operating expensesDepreciation and amortization388353776701
Operating expensesLoss (gain) on disposal of property and equipment598-636954-3,004
Operating expensesOther income, net-67-72-102-147
Operating expensesIncome from operations4,4615,0958,7578,936
Non-operating income and expensesLoss from investments162162
Non-operating income and expensesInterest expense, net248132553311
Non-operating income and expensesNet income before taxes4,0514,9638,0428,625
Non-operating income and expensesProvision for income taxes1,1511,7132,4292,665
Non-operating income and expensesNet income2,9003,2505,6135,960
Non-operating income and expensesNet income attributable to noncontrolling interest13693267178
Non-operating income and expensesNet income attributable to Viemed Healthcare, Inc.2,7643,1575,3465,782
Net income per shareBasic0.070.080.140.15
Net income per shareDiluted0.070.080.130.14
Weighted average number of common shares outstanding:Basic38,245,49139,515,24738,336,53439,471,244
Weighted average number of common shares outstanding:Diluted41,125,71641,083,76040,851,50641,393,523

Income Statement

For the quarter ended — (Expressed in thousands of U.S. Dollars)

June 30, 2026March 31, 2026December 31, 2025September 30, 2025June 30, 2025March 31, 2025December 31, 2024September 30, 2024
Net income attributable to Viemed Healthcare, Inc.2,7642,5825,6393,5133,1572,6254,3163,878
Add back:Depreciation & amortization7,5207,6217,5707,5396,8916,6136,3666,408
Add back:Interest expense, net248305364507132179147225
Add back:Stock-based compensation(a)2,0322,4512,3002,1802,3412,3111,5211,712
Add back:Transaction costs(b)7413984753851112
Add back:Impairment of assets(c)125
Add back:Income tax expense1,1511,2782,1911,5351,7139521,8811,594
Add back:Adjusted EBITDA13,71514,31118,20316,12114,28712,76514,24213,954

Balance Sheet

At June 30, 2026 — (Unaudited)

At June 30, 2026At December 31, 2025
Current assetsCash and cash equivalents10,68013,501
Current assetsAccounts receivable, net32,22925,586
Current assetsInventory5,2685,047
Current assetsIncome tax receivable227
Current assetsPrepaid expenses and other assets5,7884,132
Current assetsTotal current assets53,96548,493
Long-term assetsProperty and equipment, net77,15978,775
Long-term assetsOperating lease right-of-use assets4,5313,580
Long-term assetsEquity investments3,1842,794
Long-term assetsDeferred tax asset5,2895,289
Long-term assetsIdentifiable intangibles, net1,1581,285
Long-term assetsGoodwill58,93858,938
Long-term assetsTotal long-term assets150,259150,661
Long-term assetsTOTAL ASSETS204,224199,154
Current liabilitiesTrade payables10,9867,333
Current liabilitiesDeferred revenue8,0037,520
Current liabilitiesIncome taxes payable1,830
Current liabilitiesAccrued liabilities24,94123,910
Current liabilitiesOperating lease liabilities, current portion1,4161,203
Current liabilitiesCurrent portion of long-term debt7171,090
Current liabilitiesTotal current liabilities47,89341,056
Long-term liabilitiesAccrued liabilities900922
Long-term liabilitiesOperating lease liabilities, less current portion3,0932,364
Long-term liabilitiesLong-term debt6,37411,291
Long-term liabilitiesTotal long-term liabilities10,36714,577
Long-term liabilitiesTOTAL LIABILITIES58,26055,633
SHAREHOLDERS' EQUITYCommon stock - No par value: unlimited authorized; 38,088,228 and 38,019,082 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively17,98116,912
SHAREHOLDERS' EQUITYAdditional paid-in capital17,81021,742
SHAREHOLDERS' EQUITYRetained earnings108,237102,891
SHAREHOLDERS' EQUITYTOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY144,028141,545
SHAREHOLDERS' EQUITYNoncontrolling interest in subsidiary1,9361,976
SHAREHOLDERS' EQUITYTOTAL SHAREHOLDERS' EQUITY145,964143,521
SHAREHOLDERS' EQUITYTOTAL LIABILITIES AND SHAREHOLDERS' EQUITY204,224199,154

Cash Flow

Six Months Ended June 30, — (Unaudited)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activitiesNet income5,6135,960
Adjustments for:Depreciation and amortization15,14113,504
Adjustments for:Stock-based compensation expense4,4834,652
Adjustments for:Loss (gain) on disposal of property and equipment954-3,004
Adjustments for:Amortization of deferred financing costs13264
Adjustments for:Deferred income tax benefit-1,961
Adjustments for:Loss from other investments162
Changes in working capital:Accounts receivable, net-6,643-1,638
Changes in working capital:Inventory-221-4

Cash Flow

For the quarter ended — (Expressed in thousands of U.S. Dollars; unaudited)

TTM – June 30, 2026For the quarter ended – June 30, 2026For the quarter ended – March 31, 2026For the quarter ended – December 31, 2025For the quarter ended – September 30, 2025
Net cash provided by operating activities60,78115,9028,07118,44118,367
Less:Purchase of property and equipment-31,545-8,460-6,712-8,737-7,636
Less:Proceeds from sale of property and equipment5,1971,1741,2271,1251,671
Less:Net CAPEX-26,348-7,286-5,485-7,612-5,965
Less:Free cash flow34,4338,6162,58610,82912,402
Full release

Forward-Looking Statements... (truncated)ments”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's 2026 net revenue, Adjusted EBITDA and net capital expenditure guidance, anticipated patient and revenue growth, expected operating leverage, technology and personnel investments, capital allocation priorities, share repurchases and future cash generation, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

Use of Non-GAAP Financial Information and Financial Guidance

This press release includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company’s consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the tables accompanying this release.... (truncated)teristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. The Company’s financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Viemed Healthcare earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.